United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Dozens of drugmakers are developing COVID-19 vaccines and gearing up to produce billions of doses each year.

Is a COVID-19 Vaccine Supply Glut on the Way?

ANI Pharma

Lannett Company

Mylan

Taro Pharmaceutical Industries

Teva Pharmaceutical

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Both pharmaceutical giants are developing coronavirus vaccines. Which is a better buy?

Better Coronavirus Stock: Pfizer or GlaxoSmithKline?

Pfizer Inc  said on Tuesday it will invest up to $500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker's scientific expertise.

Pfizer to invest up to $500 million in public drug developers

The drugmaker says it will still hit its revenue-growth projections, but that will be difficult.

Are Pfizer's Growth Prospects in Trouble With Its Shocking Ibrance Setback?

Pfizer Inc. PFE, -7.14% said Tuesday it is planning to invest up to $500 million in biotech companies to support the sector's most promising clinical development programs.

Pfizer to invest up to $500 million in small and medium-sized biotech companies

Pfizer NYSE: PFE Weekly Chart On Friday, Pfizer (PFE) announced they had halted a Phase 3 breast cancer drug trial as the results were unlikely to meet their primary endpoint. Today, PFE is down over 8% midway through the U.S.

Pfizer (PFE) Sells Off as Drug Trial Halted – Where’s The Buy Zone?

Apple

Zoom Video

Blue Apron

CrowdStrike

Zoom Video, Apple, Pfizer, Blue Apron and CrowdStrike were our top stock trades for Tuesday. That said, let's look at the charts.

5 Top Stock Trades for Tuesday: AAPL, ZM, CRWD, PFE, APRN

Shares of Pfizer fell nearly 7 percent on Monday after an independent data monitoring committee determined the drugmaker’s breast cancer treatment was unlikely to meet the main goal of a late-stage study. The treatment, Ibrance, was being tested along with the standard of care for early breast cancer in men and women, against standard of.

Pfizer shares tumble after setback with breast cancer treatment

Pfizer Inc. shares were declining steeply Monday after the company said a Phase 3 study dubbed PALLAS that evaluated its Ibrance with standard adjuvant endocrine therapy in HR+, HER-, early stage breast cancer study is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring Committee.

Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals

The biopharma giant reported disappointing late-stage trial results for one of its best-selling medicines.

Why Pfizer's Shares Are Slipping 7.6% Today

In trading on Monday, shares of Pfizer crossed below their 200 day moving average of $36.59, changing hands as low as $35.15 per share. Pfizer shares are currently trading down about 7.7% on the day.

Notable Two Hundred Day Moving Average Cross - Pfizer

Shares of Pfizer Inc  fell nearly 8% on Monday after an independent data monitoring committee determined the drugmaker's breast cancer treatment was unlikely to meet the main goal of a late-stage study.

Pfizer declines about 8% after setback to breast cancer treatment

Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.

Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study

Pfizer said its blockbuster drug, Ibrance, failed to make a difference in early-stage breast cancer — leading PFE stock to tumble Monday. Ibrance is already approved in late-stage cancer.

Pfizer Stock Dives After Blockbuster Cancer Drug Flops In Late-Stage Test

Share of Pfizer Inc. PFE, +0.02% tumbled 6.5% in premarket trading Monday, enough to pace all of the Dow Jones Industrial Average' DJIA, -0.06% s early decliners after the drug maker said it halted a study of a potential breast-cancer treatment.

Pfizer's stock tumbles to pace the Dow's decliners, would cut about 17 points off the Dow's price

Chevron

Verizon

Exxon Mobil

Dogs of the Dow have large customer base, sustainable business model, a long track of profitability and strong liquidity, which allow them to offer sizable yields regardless of market conditions.

5 Dogs of the Dow for the Month of June

Despite the setback, Pfizer maintains its revenue growth projections.

Pfizer Breast Cancer Drug Posts "Disappointing" Results in Clinical Trials

Generics businesses command high margins, so even at lower multiples their valuations are significant, so we estimate the fair value of the Pfizer net of Upjohn.

Pfizer: Set Limit Orders No Higher Than $33.94

Pfizer (NYSE: PFE) shares were trading lower after disappointing news concerning its Phase 3 early breast cancer Palbociclib Collaborative Adjuvant Study (PALLAS) trial results.

Pfizer Falls On Disappointing Breast Cancer PALLAS Study

Pfizer Inc. PFE, +0.02% shares fell 7% in after-hours trading Friday after the company reported that a study of a potential breast-cancer treatment was halted because it was unlikely to achieve its goal.

Pfizer stock plunges 7% after breast cancer study halted

Microsoft

Dow Jones' journey past 25,000 points this week could mark the beginning of a series of gains ahead, owing to some major tailwinds.

4 Stocks to Watch as Dow Breezes Past 25,000 Points

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?

Bristol-Myers

The stock price for Bristol-Myers Squibb is up by roughly 15% in the last few years (since Jan 2017), driven by the company’s increased market share in the anticoagulants market. In comparison, Pfizer, one of the largest U.S.

Is Pfizer’s 2x Price Rise Versus Bristol-Myers Squibb Justified?

Corning

CORNING, NY, May  28, 2020  (GLOBE NEWSWIRE) --  ﻿ ﻿Corning Incorporated (NYSE: GLW) and  Pfizer Inc . (NYSE: PFE) today announced the execution of a long-term purchase and supply agreement for  Corning Valor  ®   Glass .

News for Pfizer Stock (PFE)